Evaluation of Same-Day versus Next-Day Implantation of Intracanalicular Dexamethasone for the Control of Postoperative Inflammation and Pain Following Cataract Surgery

References

• Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database Syst Rev. 2017;7. doi:10.1002/14651858.CD010516.pub2
   PubMed Web of Science ®Google Scholar
• Cooke DL, Cooke TL. Comparison of 9 intraocular lens power calculation formulas. J Cataract Refract Surg. 2016;42(8):1157–1164. doi:10.1016/j.jcrs.2016.06.029
   PubMed Web of Science ®Google Scholar
• Chang DT, Herceg MC, Bilonick RA, Camejo L, Schuman JS, Noecker RJ. Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma. Clin Ophthalmol. 2009;3:345. doi:10.2147/OPTH.S5730
   Google Scholar
• Porela-Tiihonen S, Kokki H, Kaarniranta K, Kokki M. Recovery after cataract surgery. Acta Ophthalmol. 2016;94(Suppl 2):1–34. doi:10.1111/aos.13055
   PubMed Web of Science ®Google Scholar
• Zafar S, Wang P, Schein OD, Srikumaran D, Makary M, Woreta FA. Prescribing patterns and costs associated with postoperative eye drop use in Medicare beneficiaries undergoing cataract surgery. Ophthalmology. 2020;127(5):573–581. doi:10.1016/j.ophtha.2019.11.005
   Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533–540. doi:10.1016/j.ajo.2007.06.012
   PubMed Web of Science ®Google Scholar
• Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189–192. doi:10.1097/IJG.0b013e31820bd2e1
   PubMed Web of Science ®Google Scholar
• An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857–1861. doi:10.1016/j.jcrs.2014.02.037
   PubMed Web of Science ®Google Scholar
• Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a Phase I/II clinical trial. Am J Ophthalmol. 2017;175:137–147. doi:10.1016/j.ajo.2016.11.020
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi:10.1016/j.ophtha.2020.06.018
   PubMed Web of Science ®Google Scholar
• Walters T, Bafna S, Vold S, et al. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies. J Clin Exp Ophthalmol. 2016;7(4). doi:10.4172/2155-9570.1000572
   Google Scholar
• Walters T, Endl M, Elmer TR, Levenson J, Majmudar P, Masket S. Sustained-release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2015;41(10):2049–2059. doi:10.1016/j.jcrs.2015.11.005
   PubMed Web of Science ®Google Scholar
• Suñer IJ, Peden MC. Dexamethasone sustained-release intracanalicular insert for control of postoperative inflammation after pars plana vitrectomy. Clin Ophthalmol. 2021;15:3859. doi:10.2147/OPTH.S330255
   Web of Science ®Google Scholar
• Trivedi RH, Wilson ME. A sustained-release intracanalicular dexamethasone insert (Dextenza) for pediatric cataract surgery. J AAPOS. 2021;25(1):43–45. doi:10.1016/j.jaapos.2020.10.001
   PubMed Web of Science ®Google Scholar
• Ibach MJ, Shafer BM, Wallin DD, Puls-Boever KR, Thompson VM, Berdahl JP. The effectiveness and safety of Dextenza 0.4 mg for the treatment of postoperative inflammation and pain in patients after photorefractive keratectomy: the RESTORE trial. J Refract Surg. 2021;37(9):590–594. doi:10.3928/1081597X-20210610-05
   PubMed Web of Science ®Google Scholar
• Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204–212. doi:10.1016/j.jcrs.2018.09.023
   PubMed Web of Science ®Google Scholar
• Greenwood MD, Gorham RA, Boever KR. A randomized fellow-eye clinical trial to evaluate patient preference for dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms following bilateral femtosecond laser in site keratomileusis (LASIK). Clin Ophthalmol. 2020;14:2223. doi:10.2147/OPTH.S265311
   PubMed Web of Science ®Google Scholar
• Foster B. Same-day versus next-day dexamethasone intracanalicular insert administration for inflammation and pain control following cataract surgery: a retrospective analysis. Clin Ophthalmol. 2021;15:4091–4096. doi:10.2147/OPTH.S335764
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–1316. doi:10.1016/j.ophtha.2015.03.026
   PubMed Web of Science ®Google Scholar
• Lee A, Blair HA. Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs. 2020;1–8. doi:10.1007/s40265-019-01241-7
   Web of Science ®Google Scholar
• Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot of dexamethasone in beagle dogs. J Ocul Pharmacol Ther. 2016;32(9):595–600. doi:10.1089/jop.2016.0025
   PubMed Web of Science ®Google Scholar
• Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279–1289. doi:10.1080/17425255.2016.1209481
   PubMed Web of Science ®Google Scholar